Structural changes in the internal domain of CD20 antigen associated with the emergence of rituximab resistance: Effects of proteasome inhibition in CD20 structure and rituximab anti-tumor activity in rituximab-resistant cell lines (RRCL).

被引：0
|
作者：
Hernandez-Ilizaliturri, FJ [1 ]
Olejniczak, SH [1 ]
Knight, J [1 ]
Czuczman, MS [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1474
引用
收藏
页码：425A / 425A
页数：1
相关论文
共 45 条
  • [1] Structural changes in the internal domain of the CD20 antigen is associated with the development of rituximab resistance: Effects on signaling and redistribution of CD20 into lipid raft domains in rituximab-resistant cell lines (RRCL).
    Gowda, AC
    Hernandez-Ilizaliturri, FJ
    Connolly, G
    Czuczman, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 163S - 163S
  • [2] Regulation of CD20 in rituximab-resistant cell lines (RRCL) and B-cell non-Hodgkin's lymphomas (NHL)
    Tsai, Ping-Chiao
    Nayeen, Bangia
    Olejniczak, Scott
    Hernandez-Ilizaliturri, Francisco
    Czuczman, Myron
    JOURNAL OF IMMUNOLOGY, 2010, 184
  • [3] Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
    Tsai, Ping-Chiao
    Hernandez-Ilizaliturri, Francisco J.
    Bangia, Naveen
    Olejniczak, Scott H.
    Czuczman, Myron S.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1039 - 1050
  • [4] Acquirement of rituximab resistance in lymphoma cell lines is associated with structural changes in the internal domain of CD20 regulated at the post-transcriptional level.
    Czuczman, MS
    Olejniczak, S
    Gowda, AC
    Starostik, P
    Hernandez-Ilizaliturri, FJ
    BLOOD, 2004, 104 (11) : 628A - 628A
  • [5] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [6] Modulation of CD20 expression in rituximab-sensitive (RSCL) and rituximab resistant cell lines (RRCL) using IL-4 and bryostatin-1.
    Tsai, Ping-Chiao
    Hernandez-Ilizaliturri, Francisco J.
    Olejniczak, Scott H.
    Naveen, Bangia
    Czuczman, Myron S.
    BLOOD, 2007, 110 (11) : 771A - 772A
  • [7] ALTERED CD20 CONFORMATION AT THE CELL SURFACE OF RITUXIMAB REFRACTORY TUMOR CELLS - A NOVEL MECHANISM OF RITUXIMAB RESISTANCE
    Shimada, K.
    Tomita, A.
    Tokunaga, T.
    Iriyama, C.
    Kinoshita, T.
    Glennie, M.
    Johnson, P.
    Naoe, T.
    ANNALS OF ONCOLOGY, 2011, 22 : 241 - 241
  • [8] Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.
    Barth, M. J.
    Hernandez-Ilizaliturri, F. J.
    Mavis, C.
    Tsai, P.
    Gibbs, J. F.
    Czuczman, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Impaired Ca plus plus mobilization in rituximab-resistant cells is associated with changes in the structure of CD20 antigen and downregulation of Bax/Bak pro-apoptotic proteins
    Hernandez-Ilizaliturri, Francisco J.
    Bhinder, Arvinder
    Olejniczak, Scott
    Knight, Joy
    Czuczman, Myron S.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Cooperation Between the CD20 Receptor and hIFN-Alpha Receptor in Overriding the Blocked CD20 Cell-Signaling in Rituximab-Resistant B-NHL By the Fusion Protein Anti-CD20-hIFN-Alpha
    Vega, Gabriel G.
    Franco-Cea, Luz A.
    Huerta-Yepez, Sara
    Mayani, Hector
    Martinez-Maza, Otoniel
    Bonavida, Benjamin
    Vega, Mario I.
    BLOOD, 2015, 126 (23)
12345